Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine

Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine
Country
Agency
Status
Link
Details on adaptation
Contact information
(Scotland)
HIS
Published July 2015
Link to report
The EUnetHTA report was referenced in discussion on impact of sorafenib on health related quality of life.
Jan Jones janjones@nhs.net
Belgium
RIZIV
Used in cross-checking evidence.
Francis Arickx francis.arickx@riziv.fgov.be
Belgium
KCE
Link to summary
Analysis of scientific context and its relevance, “KCE has read for you”.
Patrice Chalon patrice.chalon@kce.fgov.be
Croatia
AAZ
2015
Summary of information from the report for decision makers and website
Mirjana Huic (Mirjana.Huic@aaz.hr)
Portugal
INFARMED
Used in direct decision-making.
João Martins joao.martins@infarmed.pt
Slovakia
MoH SK
Used in direct decision-making.
Tomas Tesar tomas.tesar@union.sk
Spain
IACS
Used in direct decision-making.
Almudena Albertos aalbertos@isciii.es
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.